Locations:
Search IconSearch
October 6, 2023/Cancer

New Consensus Statement Addresses Early Management of Ewing Sarcoma

Multicenter effort aims to standardize information about diagnosis and early management

Matteo Trucco, MD

By Matteo Trucco, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Despite being the second most common bone malignancy seen in children and adolescents, only 200 to 250 cases of Ewing sarcoma are diagnosed in the United States annually. As such, while there is a good chance a patient with Ewing sarcoma is receiving care at a pediatric oncology practice, it is difficult for centers and practitioners to see the volume necessary to truly acquire expertise with this rare and challenging tumor.

The management of these patients is further complicated by heterogeneous presentations, including long bones, axial skeleton, chest wall, soft tissue and occasionally tumors arising in organs. In addition, while collaborative groups and even international trials have attempted to standardize the management, at least upfront, of Ewing sarcoma, the literature and data are often murky or incomplete, leading to many questions and confusion about how to treat patients with the disease.

In 2021, a generous donation from the Carson Sarcoma Foundation to support the laboratory research of Jacob Scott, MD, DPhil, a physician-researcher at Cleveland Clinic, helped facilitate a comprehensive and multidisciplinary initiative to connect Ewing sarcoma specialists across Cleveland Clinic and in large sarcoma centers throughout the U.S.

To achieve this, the National Ewing Sarcoma (NEWS) Tumor Board, a monthly virtual tumor board with multidisciplinary experts in Ewing sarcoma from across the country, was established to discuss challenging cases and provide education about various strategies to manage the disease, including clinical trials available throughout the country. Since July 2021, the NEWS Tumor Board has been held monthly with, on average, 40 oncologists, surgeons, radiation oncologists, radiologists and pathologists in attendance. Typically, one to four cases are discussed during each tumor board.

Advertisement

Leveraging expertise

We took advantage of the combined expertise of the participants of the NEWS Tumor Board and wrote a manuscript that highlights and provides consensus and guidance on some of the questions frequently encountered in the management of Ewing sarcoma. It was quickly determined that one paper was not sufficient to address all the questions surrounding Ewing sarcoma management, so questions regarding the upfront management of newly diagnosed Ewing sarcoma were chosen for the first manuscript. In July 2023, the first consensus paper of the NEWS Tumor Board was published in Cancer.

Key recommendations on workup and treatment

This collaborative effort aimed to answer questions regarding the most appropriate workup and management for Ewing sarcoma patients. Most notably, we address topics related to workup, including PET/CT versus bone scan and the necessity of bone marrow evaluation. Regarding treatment, topics range from the use of interval compressed therapy in adult patients, the appropriate number of chemotherapy cycles, the discrepancy between current accepted practice and past studies for the addition of ifosfamide/etoposide in patients with metastatic disease, the role of high-dose chemotherapy with autologous stem cell rescue for the upfront treatment of Ewing sarcoma, the role of maintenance chemotherapy, and the role of whole lung radiation.

The data on many – if not all – of these topics is sparse, incomplete, old, conflicting and controversial. This group of experts, organized by the team at Cleveland Clinic, sought to shed light and insight on these topics and offer consensus statements to help guide clinicians who are treating patients with this challenging and often frustrating disease. We are heartened that the paper has been well-received, including from reviewers who have extolled its value. To date, it has received more than 600 full-text views on the journal’s website.

Advertisement

A look ahead

A second manuscript is in preparation addressing common questions and issues related to the management of Ewing sarcoma in the relapsed setting along with additional papers that are being proposed and discussed.

About the author: Dr. Trucco is staff in Cleveland Clinic Children’s Department of Hematology, Oncology and Blood and Marrow Transplantation.

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Ad